Providence, Rhode Island, U.S., September 21, 2026

Nabsys 2.0, LLC, a company developing Electronic Genome Mapping (EGM) technology, has announced the publication of a new preprint demonstrating a CRISPR/Cas9-mediated approach to expand the capabilities of electronic genome mapping. The study represents the first publication combining CRISPR/Cas9 with EGM and demonstrates how the genome-editing technology can be used to customize the genomic information generated by EGM. The research could broaden the use of electronic genome mapping beyond conventional genome-wide structural variant analysis by enabling investigators to focus on specific complex genomic regions. According to Nabsys, the approach may be particularly valuable for genomic regions that are difficult to characterize using established cytogenetic or sequencing methods.

CRISPR/Cas9 Expands Electronic Genome Mapping

The study, titled CRISPR/Cas9 Optimization Using Electronic Genome Mapping: Potential Role for Studying Human Genetic Disease, was led by John F. Thompson, Ph.D., Principal Application Scientist at Nabsys, and his research team. The investigators demonstrated that EGM can be used to characterize CRISPR/Cas9 activity and support optimization of guide RNA, or gRNA, sequences. EGM enables genome-wide assessment of CRISPR/Cas9 binding and can provide information about the effects of gRNA and PAM sequences at intended target sites as well as potential off-target locations. This capability may be important as CRISPR-based approaches continue to develop in research involving cell and gene therapies, where understanding targeting performance is a critical component of genome-editing development.

The research also demonstrates how CRISPR/Cas9 can be used to enhance EGM itself. By selectively modifying labeling patterns within DNA, the researchers demonstrated approaches involving targeted DNA labeling, label blocking, and label insertion. Combining these capabilities allows researchers to use EGM for both broad genome-wide analysis and targeted investigation of selected genomic regions. This could expand the technology’s potential applications in research involving complex structural variation and difficult-to-study portions of the human genome.

Nabsys Links EGM With Genetic Disease Research

Advertisement

cGxPJobs Banner

A key component of the study was the demonstration of CRISPR-mediated EGM for investigating human genetic disease. The researchers used the approach to detect repeat expansions in the FXN gene, which are associated with Friedreich ataxia, a genetic neurological disorder. Nabsys stated that the methodology could potentially be extended to other repeat expansion disorders, including investigations involving FMR1 repeats associated with Fragile X syndrome. These applications highlight the potential of targeted electronic genome mapping for studying genomic regions that can present challenges for other analytical technologies. Repeat expansions and other complex genomic alterations can be difficult to analyze because conventional methods may not always provide sufficient information about the structure or extent of genomic changes. By combining the targeting capabilities of CRISPR/Cas9 with the long-molecule analysis capabilities of EGM, the Nabsys approach is designed to provide researchers with additional information about specific regions while retaining broader genomic context. The company said the study demonstrates that EGM can function as both a genome-wide and targeted analytical approach.

OhmX Platform Supports Genomics Innovation

Nabsys’ OhmX Platform uses proprietary Electronic Genome Mapping technology to analyze ultra-long DNA molecules electronically. The platform combines electronic detection, nanofluidics and computational biology to generate high-resolution information about genome structure. Unlike traditional genome mapping systems that rely heavily on lasers, cameras and complex optical components, EGM is designed around an electronic detection approach in a compact platform. Nabsys is developing the technology for applications spanning cytogenetics, molecular genetics, structural variation analysis, rare disease research and cell and gene therapy research. The new publication represents an important research milestone for Nabsys as the company explores ways to extend EGM beyond conventional structural variant analysis.

By combining CRISPR/Cas9 targeting with electronic genome mapping, the research introduces a potential strategy for examining difficult genomic regions with greater flexibility. The company indicated that the work could support future applications involving additional genes and genomic disorders. For the life sciences technology sector, the development illustrates how CRISPR genome editing, ultra-long DNA analysis and electronic genome mapping can be integrated to investigate complex genetic information. The OhmX Platform remains designated for Research Use Only, and the findings represent research applications rather than a clinical diagnostic or therapeutic approval.

Source: Nabsys press release